Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus DICE in R/R B-cell NHL
NCT03105596Phase 2Unknown
- Sponsor
- Peking University
- Start
- Apr 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in B-cell non-Hodgkin lymphoma, sponsored by Peking University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03105596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105596.